Debt-to-equity of Lineage Cell Therapeutics, Inc. from 31 Mar 2017 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Lineage Cell Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2017 to 30 Sep 2025.
  • Lineage Cell Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 80%, a 50% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Lineage Cell Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 80% +27% +50% 30 Sep 2025
Q2 2025 54% -2.2% -3.9% 30 Jun 2025
Q1 2025 47% -9.3% -16% 31 Mar 2025
Q4 2024 50% -9.8% -17% 31 Dec 2024
Q3 2024 53% -8.4% -14% 30 Sep 2024
Q2 2024 56% -8.5% -13% 30 Jun 2024
Q1 2024 57% -10% -15% 31 Mar 2024
Q4 2023 59% -8.7% -13% 31 Dec 2023
Q3 2023 62% -12% -16% 30 Sep 2023
Q2 2023 64% +9.6% +18% 30 Jun 2023
Q1 2023 67% +28% +71% 31 Mar 2023
Q4 2022 68% +42% +163% 31 Dec 2022
Q3 2022 74% +63% +621% 30 Sep 2022
Q2 2022 55% +43% +387% 30 Jun 2022
Q1 2022 39% +26% +207% 31 Mar 2022
Q4 2021 26% +12% +88% 31 Dec 2021
Q3 2021 10% -3.3% -25% 30 Sep 2021
Q2 2021 11% -2.6% -19% 30 Jun 2021
Q1 2021 13% -1.3% -9.1% 31 Mar 2021
Q4 2020 14% -0.33% -2.3% 31 Dec 2020
Q3 2020 14% -0.18% -1.3% 30 Sep 2020
Q2 2020 14% +3.4% +32% 30 Jun 2020
Q1 2020 14% +5.2% +60% 31 Mar 2020
Q4 2019 14% +7.4% +109% 31 Dec 2019
Q3 2019 14% +8% +138% 30 Sep 2019
Q2 2019 10% +3.8% +58% 30 Jun 2019
Q1 2019 8.7% +1.7% +24% 31 Mar 2019
Q4 2018 6.8% -0.5% -6.9% 31 Dec 2018
Q3 2018 5.8% -2.4% -29% 30 Sep 2018
Q2 2018 6.6% -2.4% -26% 30 Jun 2018
Q1 2018 7.1% -2.6% -27% 31 Mar 2018
Q4 2017 7.2% 31 Dec 2017
Q3 2017 8.2% 30 Sep 2017
Q2 2017 9% 30 Jun 2017
Q1 2017 9.6% 31 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.